Moderna and Merck Announce Positive Melanoma Vaccine Trial Results
Moderna and Merck have reported encouraging results from a trial of their mRNA-based melanoma vaccine, showing it prevents the return of the cancer. This news led to a significant surge in the stock prices of both pharmaceutical companies.
The Story
Analyzing sources…
Source Diversity
Source Diversity
Excellent (100/100)Sources
Moderna, Merck Say mRNA Vaccine Prevents Melanoma From Returning
The companies say the vaccine prevented the return and spread of the cancer in high-risk melanoma patients.
By Carolyn Y. Johnson
Read full article →Merck, Moderna Stocks Soar After Melanoma Trial Success
Shares of Moderna and Merck soared on Wednesday morning after a study showed that a vaccine they produced had promising results when it comes to fighting skin cancer. A late-stage trial showed that the mRNA vaccine helped reduce the recurrence of melanoma. Sam Fazeli of Bloomberg Intelligence has more. (Source: Bloomberg)
Read full article →Moderna’s cancer shot: exciting for investors, inconclusive for patients
A glimmer of hope for sufferers, a potential revenue platform for a cash-burner, and a whole heap of unknowns
Read full article →Personalized cancer vaccine from Moderna, Merck shows promise in first late-stage melanoma trial
The combination regimen significantly extended the time patients lived without their melanoma returning, compared with Keytruda alone.
Read full article →Merck, Moderna claim encouraging melanoma vaccine trial results
US pharmaceutical firms Merck and Moderna announced on Wednesday encouraging results from a trial of their experimental vaccine against melanoma, potentially clearing the way for approval. The vaccine, called intismeran autogene, showed “statistically significant and clinically meaningful improvements” for skin cancer patients when used with Merck’s Keytruda treatment, the companies said in a statement. Unlike conventional vaccines, so-called therapeutic vaccines like intismeran treat rather...
By Agence France-Presse
Read full article →Moderna’s stock doubles on promising cancer-vaccine results
The vaccine candidate pairs an mRNA therapy with the cancer drug Keytruda.
By Jaimy Lee
Read full article →Moderna Shares Skyrocket 95% Toward Best Day Ever—On Success Of Cancer Drug Trial
The trial marked the first successful final-stage study for any mRNA-based cancer therapy.
By Ty Roush, Forbes Staff
Read full article →Moderna stock jumps 120% after cancer vaccine trial win: What investors need to know
Moderna stock surged after its mRNA cancer vaccine showed positive Phase 3 results with Merck’s Keytruda, boosting hopes for a new melanoma treatment.
Read full article →Moderna surges on trial win for cancer shot; William Blair upgrades
Read full article →Moderna shares jump 60% on melanoma vaccine trial
Shares in pharma giant Moderna soared about 60% in premarket trading after the company, in a joint statement with Merck, said its mRNA vaccine, combined with Merck's immunothe...
Read full article →Holy Grail In Cancer Treatment? Moderna Erupts After Melanoma Vaccine Late-Stage Trial Success
Holy Grail In Cancer Treatment? Moderna Erupts After Melanoma Vaccine Late-Stage Trial Success Moderna's shares soared as much as 83% in premarket trading in New York after its personalized cancer vaccine, developed in collaboration with Merck & Co., reduced the risk of melanoma returning in a large, late-stage trial. The result marks the first positive Phase 3 trial for a personalized cancer vaccine by any company. The study met its primary endpoint by showing that the cancer ...
By Tyler Durden
Read full article →
